Gene expression changes between clinical time points of active TA-TMA and TA-TMA resolution in 4 autologous HSCT recipients with TA-TMA. The figure shows a section of the heatmap that illustrates the change in complement and interferon gene expression profiles in patients with TA-TMA. “TMA diagnosis” indicates gene expression changes from pretransplant baseline compared with when TA-TMA was diagnosed posttransplant, but before initiating complement-blocking therapy with eculizumab. “TMA resolution” indicates gene expression changes from when TA-TMA was diagnosed compared with clinical resolution of TA-TMA, after completing eculizumab therapy. Genes shown are upregulated at the time of TA-TMA diagnosis (FDR < 0.1) and belong to at least of 1 of the enriched pathway or gene lists shown in Table 1. Green bars on the right side indicate statistically significant changes at the time of TA-TMA resolution (FDR < 0.1). Data indicate that complement pathways are highly upregulated at TA-TMA diagnosis in subjects with TA-TMA and normalize after resolution of TA-TMA.